LMX1B Lentiviral Activation Particles (h): sc-402945-LAC
- Target species: human
- 200 µl of transduction-ready, high-titer CRISPR/dCas9 Lentiviral Activation Particles
- LMX1B Lentiviral Activation Particles (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically and efficiently upregulate gene expression via lentiviral transduction of cells
- LMX1B Lentiviral Activation Particles (h) contain the following SAM Activation elements: a deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, an MS2-p65-HSF1 fusion protein and a target-specific 20 nt guide RNA. They also contain the blasticidin, hygromycin and puromycin resistance genes
- Upon transduction, the SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by LMX1B Lentiviral Activation Plasmid (h) and LMX1B Lentiviral Activation Plasmid (h2) target distinct regulatory regions of the LMX1B promoter. One or both designs may be available
- Following transfection, gene activation efficiency can be assayed by WB, IF or IHC using antibody: LMX1B Antibody (1D12): sc-293262
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
LMX1B Lentiviral Activation Particles (h) | sc-402945-LAC | 200 µl | $455.00 |
LMX1B encodes a LIM homeobox transcription factor that directs cell fate specification and differentiation programs during development, with particularly strong roles in dorsal limb patterning, glomerular podocyte maturation, and midbrain dopaminergic neuron identity. By binding regulatory DNA elements and coordinating cofactor-dependent transcriptional networks, LMX1B influences pathways governing cytoskeletal organization, extracellular matrix dynamics, and lineage-restricted gene expression. Altered LMX1B activity is linked to congenital limb and kidney phenotypes and is frequently studied in contexts of podocyte dysfunction, developmental gene regulation, and neuronal specification. As a nuclear transcriptional regulator, LMX1B serves as a tractable node for dissecting gene regulatory circuitry and enhancer-driven control of tissue-specific programs.
LMX1B Lentiviral Activation Particles (h) address this need by packaging the complete synergistic activation mediator (SAM) transcriptional activation system into transduction-ready, high-titer lentiviral particles, enabling efficient LMX1B upregulation across a broader range of human cell types.
LMX1B Lentiviral Activation Particles (h) deliver all functional components of the synergistic activation mediator (SAM) system via lentiviral transduction. The system comprises three particle preparations co-transduced into target cells: one encoding catalytically inactive dCas9 (D10A and N863A mutations) fused to the VP64 transactivation domain with a blasticidin resistance gene; one encoding the MS2-p65-HSF1 fusion protein with a hygromycin resistance gene; and one encoding a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers with a puromycin resistance gene. Following lentiviral transduction and genomic integration of the expression cassettes, the SAM components are stably expressed and assemble at the target locus within the proximal promoter region upstream of the LMX1B transcriptional start site, where VP64, p65, and HSF1 act cooperatively to recruit endogenous transcriptional machinery and drive sustained upregulation of endogenous LMX1B expression. The use of nuclease-inactive dCas9 avoids the introduction of double-strand DNA breaks and preserves the native LMX1B genomic locus and regulatory architecture.
The lentiviral format offers several practical advantages: stable genomic integration supports heritable activation across cell divisions; high-titer particle preparations eliminate the need for in-house viral production; and compatibility with primary, non-dividing, and transfection-resistant cell types expands experimental accessibility. Successful transduction can be confirmed and enriched through triple antibiotic selection using puromycin, hygromycin, and blasticidin.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.